ArticleIndian journal of sexually transmitted diseases and AIDS
Predictors of serological cure and serofast stage after treatment in patients with syphilis: A retrospective study from India.
Article in Indian journal of sexually transmitted diseases and AIDS. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Patients with syphilis, who receive appropriate treatment, fail to achieve serological cure and have persistent nontreponemal titers. This study was conducted to analyze the factors associated with serofast stage after the treatment of patients. Methods: A retrospective study was conducted from January 2019 to June 2022, involving 70 patients with syphilis who were followed up for 12 months using the Venereal Disease Research Laboratory (VDRL) test. Results: Primary syphilis was observed in 11.4% (8), secondary syphilis in 77.2% (54), and latent syphilis in 11.4% (8) of the patients. The serological cure rates at 3, 6, 9, and 12 months were 10% (7/70), 41.4% (29/70), 50% (35), and 62.8% (44), respectively. Patients <25 years and with higher baseline VDRL titers (>1:16) had a better response to treatment. HIV-positive patients had 1.7-fold higher odds of serological failure compared to HIV-negative patients. Conclusion: In conclusion, our study underscores the need for tailored approaches to syphilis management and highlights the importance of ongoing research to enhance our understanding of treatment response predictors and optimize patient outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.